LL-37 is a human cathelicidin antimicrobial peptide composed of 37 amino acids, derived from the C-terminal portion of the precursor protein hCAP18. It is widely studied for its role in innate immunity, wound healing, and inflammatory modulation. LL-37 exhibits broad-spectrum antimicrobial activity and is involved in regulating immune cell chemotaxis, cytokine release, and epithelial barrier defense. In vitro research also explores its effects on angiogenesis, cell proliferation, and tissue repair.